INmune Bio Inc
NASDAQ:INMB

Watchlist Manager
INmune Bio Inc Logo
INmune Bio Inc
NASDAQ:INMB
Watchlist
Price: 7.38 USD 0.27% Market Closed
Market Cap: 171.3m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+339%
Revenue
Forecast
N/A
Operating Income
Forecast
+1%
Net Income
Forecast
+12%

Wall Street
Price Targets

INMB Price Targets Summary
INmune Bio Inc

Wall Street analysts forecast INMB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for INMB is 23.87 USD with a low forecast of 20.2 USD and a high forecast of 31.5 USD.

INMB Lowest Forecast
Wall Street Target
20.2 USD
174% Upside
INMB Average Forecast
Wall Street Target
23.87 USD
223% Upside
INMB Highest Forecast
Wall Street Target
31.5 USD
327% Upside
Lowest
Price Target
20.2 USD
174% Upside
Average
Price Target
23.87 USD
223% Upside
Highest
Price Target
31.5 USD
327% Upside
INmune Bio Inc Competitors:
Price Targets
XGN
Exagen Inc
14% Upside
CVAC
CureVac NV
55% Upside
B
BCAX
Bicara Therapeutics Inc
266% Upside
301047
Sino Biological Inc
26% Upside
XGN
Exagen Inc
14% Upside
CVAC
CureVac NV
55% Upside
B
BCAX
Bicara Therapeutics Inc
266% Upside
301047
Sino Biological Inc
26% Upside
ELDN
Eledon Pharmaceuticals Inc
206% Upside
CSL
CSL Ltd
30% Upside
688687
Beijing Kawin Technology Share-holding Co Ltd
66% Upside
ANAB
AnaptysBio Inc
88% Upside

Revenue
Forecast

Revenue Estimate
INmune Bio Inc

The compound annual growth rate of INmune Bio Inc's revenue for the next 3 years is 944%.

N/A
Past Growth
944%
Estimated Growth
Estimates Accuracy
31%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
INmune Bio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
INmune Bio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-31%
Average Miss
What are analyst estimates?

See Also

Summary
INMB intrinsic value, competitors valuation, and company profile.
DCF Valuation
INMB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
INMB stock valuation using valuation multiples.
Wall Street Estimates
INMB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
INMB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is INMB's stock price target?
Price Target
23.87 USD

According to Wall Street analysts, the average 1-year price target for INMB is 23.87 USD with a low forecast of 20.2 USD and a high forecast of 31.5 USD.

What is INmune Bio Inc's Revenue forecast?
Projected CAGR
944%

The compound annual growth rate of INmune Bio Inc's revenue for the next 3 years is 944%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.